HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis.

CONCLUSIONS: Our findings highlighted the targeting of HYOU1 as a novel therapeutic approach for the treatment of EOC.
PMID: 31173282 [PubMed - in process]

Source: European Review for Medical and Pharmacological Sciences - June 9, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research